Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19797058 | 0.95 | FFAR4 (0.40) | FFAR4SPHK1CYP2C9S1PR3S1PR1 | |
| SCHEMBL19797084 | 0.95 | FFAR4 (0.44) | FFAR4SPHK1CYP2C9 | |
| SCHEMBL19796805 | 0.92 | FFAR4 (0.38) | FFAR4SPHK1CYP2C9S1PR3CYP3A4 | |
| SCHEMBL19796802 | 0.92 | FFAR4 (0.36) | FFAR4SPHK1CYP2C9S1PR3ESR2 | |
| SCHEMBL19797118 | 0.92 | FFAR4 (0.41) | FFAR4SPHK1 | |
| SCHEMBL19797057 | 0.91 | FFAR4 (0.39) | FFAR4SPHK1CYP2C9S1PR3S1PR1 | |
| SCHEMBL19797107 | 0.91 | FFAR4 (0.43) | FFAR4SPHK1CYP2C9ESR2ALDH1A1 | |
| SCHEMBL19796864 | 0.89 | FFAR4 (0.40) | FFAR4SPHK1CYP2C9S1PR3S1PR1 | |
| SCHEMBL19797119 | 0.88 | FFAR4 (0.38) | FFAR4SPHK1CYP2C9S1PR3S1PR1 | |
| SCHEMBL19796791 | 0.88 | FFAR4 (0.36) | FFAR4SPHK1CYP2C9S1PR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689576-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10385269-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| US-20180208849-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208849-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-3327101-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20170174993-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174993-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | FFAR4 1715/4885SPHK1 608/4885CYP2C9 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.